Gene-Guided reflux drug may tame childhood asthma
NCT ID NCT03015610
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested whether adjusting the dose of a common acid reflux medicine (lansoprazole) based on a child's genes could improve asthma control. 41 children aged 6-17 with uncontrolled asthma and mild reflux participated. Researchers measured changes in asthma symptoms and reflux over 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lansoprazole
- What this could lead to
- If successful, this could lead to personalized dosing of acid reflux medicine to better control asthma in children.
- What could go wrong
- This is a small, completed Phase 3 trial with only 41 participants, so results may not apply to all children. The benefit of gene-guided dosing over standard care remains uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Nemours Children's Specialty Care
Jacksonville, Florida, 32207, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking severe asthma over time unlock better treatments?
- Can pressurized breathing boost mucus clearance in lung disease?
- Can a simple breathing test unlock the secrets of chronic cough?
- Can a Breath-Activated inhaler match the standard for asthma control?
- Can a School-Home program tame childhood asthma?
- Could everyday supplements shield your lungs?